Phibro Animal Health (NASDAQ:PAHC) Stock Price Expected to Rise, Barclays Analyst Says

Phibro Animal Health (NASDAQ:PAHC) had its price target raised by Barclays from $13.00 to $20.00 in a research report sent to investors on Tuesday morning,Benzinga reports. Barclays currently has an underweight rating on the stock.

PAHC has been the topic of several other reports. JPMorgan Chase & Co. initiated coverage on shares of Phibro Animal Health in a research note on Tuesday, September 10th. They issued a “neutral” rating and a $22.00 price objective on the stock. Bank of America lifted their price objective on shares of Phibro Animal Health from $13.00 to $15.00 and gave the company an “underperform” rating in a research note on Friday, August 30th. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $16.50.

Phibro Animal Health Stock Down 1.8 %

Shares of PAHC opened at $24.46 on Tuesday. Phibro Animal Health has a 12 month low of $9.49 and a 12 month high of $25.98. The firm’s 50 day moving average is $22.79 and its 200-day moving average is $19.69. The stock has a market capitalization of $990.63 million, a PE ratio of 56.89, a P/E/G ratio of 0.66 and a beta of 0.51. The company has a current ratio of 3.23, a quick ratio of 1.69 and a debt-to-equity ratio of 1.81.

Phibro Animal Health (NASDAQ:PAHC) last announced its earnings results on Wednesday, August 28th. The company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.34 by $0.07. Phibro Animal Health had a net margin of 1.67% and a return on equity of 21.59%. The company had revenue of $273.16 million for the quarter, compared to analysts’ expectations of $262.44 million. Equities research analysts forecast that Phibro Animal Health will post 1.59 EPS for the current year.

Phibro Animal Health Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 18th. Shareholders of record on Wednesday, November 27th will be given a $0.12 dividend. The ex-dividend date is Wednesday, November 27th. This represents a $0.48 dividend on an annualized basis and a yield of 1.96%. Phibro Animal Health’s dividend payout ratio is currently 111.63%.

Insider Buying and Selling at Phibro Animal Health

In related news, Director E Thomas Corcoran bought 5,000 shares of the business’s stock in a transaction on Wednesday, September 4th. The shares were purchased at an average price of $20.02 per share, for a total transaction of $100,100.00. Following the completion of the transaction, the director now directly owns 25,000 shares of the company’s stock, valued at approximately $500,500. This represents a 25.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 50.07% of the company’s stock.

Institutional Trading of Phibro Animal Health

Hedge funds have recently added to or reduced their stakes in the stock. CWM LLC boosted its position in Phibro Animal Health by 89.8% in the second quarter. CWM LLC now owns 2,188 shares of the company’s stock valued at $37,000 after buying an additional 1,035 shares in the last quarter. nVerses Capital LLC acquired a new position in shares of Phibro Animal Health during the third quarter worth $70,000. Quantbot Technologies LP acquired a new position in shares of Phibro Animal Health during the third quarter worth $70,000. Summit Securities Group LLC acquired a new position in shares of Phibro Animal Health during the second quarter worth $83,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Phibro Animal Health by 63.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 3,912 shares of the company’s stock worth $88,000 after purchasing an additional 1,522 shares during the period. Institutional investors and hedge funds own 99.34% of the company’s stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.